Endogenous GLP-1 Secretion On Islet Function In People With And Without Type 2 Diabetes

Overview

About this study

The purpose of this study is to determine the effect of endogenous GLP-1 secretion on islet function in people with Typr 2 Diabetes Mellitus (T2DM).

GLP-1 is a hormone made by the body that promotes the production of insulin in response to eating. However, there is increasing evidence that this hormone might help support the body’s ability to produce insulin when diabetes develops. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Twenty (20) weight stable subjects with Type 2 Diabetes Mellitus (T2DM) managed with diet or with metformin alone.
  • Twenty (20) weight- and sex-matched subjects without T2DM using similar methods.
  • No history of microvascular or macrovascular complications of T2DM.
  • Must reside within a 100 mile radius of Mayo Clinic, Rochester MN.

Exclusion Criteria:

  • N/A.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

Contact information:

Adrian Vella

5072841920

vella.adrian@mayo.edu

More information

Publications

Publications are currently not available